Suzhou Angtuo Biopharmaceutical

Angtuo Biopharma is a biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative RNA-based therapeutics. The company leverages its proprietary delivery platforms to develop small interfering RNA (siRNA) and antisense oligonucleotide (ASO) medicines targeting chronic diseases, particularly in the cardiovascular and metabolic spaces. Angtuo's lead programs focus on validated targets such as PCSK9 and AGT, aiming to provide long-acting treatment options for conditions like hypercholesterolemia and hypertension. Founded by industry experts with deep experience in RNA interference, the company is also advancing extra-hepatic delivery technologies to expand the reach of genetic medicines beyond the liver.